Welcome to our dedicated page for XLRN news (Ticker: XLRN), a resource for investors and traders seeking the latest updates and insights on XLRN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect XLRN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of XLRN's position in the market.
Acceleron Pharma (Nasdaq:XLRN), a biopharmaceutical company focused on TGF-beta therapeutics, has announced participation in two virtual healthcare investor conferences. The Cowen & Co. 41st Annual Health Care Conference is scheduled for March 2, 2021, at 2:50 p.m. EST, followed by the Barclays Global Healthcare Conference on March 9, 2021, at 10:20 a.m. EST. Live webcasts will be accessible on the company’s website, with replays available post-event. Acceleron specializes in treatments for pulmonary and hematologic diseases, including sotatercept for pulmonary arterial hypertension and REBLOZYL for certain blood disorders.
Acceleron Pharma (Nasdaq:XLRN) will host a webcast and conference call on February 25, 2021, at 5:00 p.m. EST to discuss its Q4 and full year 2020 financial results. The event will be accessible via their website under 'Events & Presentations'. The company focuses on therapeutics for serious rare diseases, with developments in pulmonary treatments, including sotatercept for pulmonary arterial hypertension (PAH) and REBLOZYL for anemia in blood disorders through a collaboration with Bristol Myers Squibb.
Bristol Myers Squibb Canada and Acceleron Pharma announced that Health Canada has approved REBLOZYL® (luspatercept) for treating adult patients with transfusion-dependent anemia due to myelodysplastic syndromes (MDS) who require at least two RBC units over eight weeks.
This marks REBLOZYL® as the first and only approved erythroid maturation agent in Canada. The approval is based on the successful results of the phase 3 MEDALIST study, where 38% of patients treated achieved transfusion independence compared to 13% on placebo.
Acceleron Pharma (Nasdaq:XLRN) reported Q4 2020 net sales of REBLOZYL at approximately $115 million, achieving total annual sales of $274 million. The company expects royalty revenue of $23 million for Q4, up from $19.3 million in Q3, leading to an estimated $54.8 million in total royalty revenue for 2020. Preliminary revenue estimates are subject to finalization and audit procedures, and thus may change. Acceleron remains focused on developing treatments for serious diseases, highlighting potential Phase 3 trials for its pulmonary candidate, sotatercept.
Acceleron Pharma (Nasdaq:XLRN) has announced that CEO Habib Dable will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 11 at 10:00 a.m. EST, in a virtual format. A live webcast of the presentation will be available on the company's website, with a replay accessible afterward.
Acceleron focuses on developing therapeutics for serious and rare diseases, specializing in pulmonary and hematologic conditions. The company is advancing sotatercept for pulmonary arterial hypertension and has a collaboration for REBLOZYL, treating anemia in blood disorders.
Acceleron Pharma has received orphan designation from the European Commission for its drug sotatercept, intended to treat pulmonary arterial hypertension (PAH). This designation offers benefits including a 10-year market exclusivity and support for clinical trials. Acceleron is advancing a Phase 3 development plan for sotatercept with the STELLAR trial expected to start soon. The drug showed promising results in the PULSAR Phase 2 trial, improving pulmonary vascular resistance and the 6-minute walk distance in patients. Sotatercept aims to become a vital treatment option for PAH.
Acceleron Pharma Inc. (Nasdaq: XLRN) announced that the FDA granted Orphan Drug designation to ACE-1334 for systemic sclerosis treatment. This designation supports the development of therapies for rare diseases affecting less than 200,000 people in the U.S. Acceleron plans to initiate a Phase 1b/Phase 2 trial for ACE-1334 in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in 2021. The company is also advancing its Phase 3 clinical program for sotatercept in pulmonary arterial hypertension (PAH).
Acceleron Pharma Inc. (Nasdaq: XLRN) announced preliminary interim data from the ongoing SPECTRA Phase 2 trial of sotatercept for pulmonary arterial hypertension (PAH). The initial findings indicate significant improvements in hemodynamic measures, with pulmonary vascular resistance (PVR) showing a 35.9% reduction and mean pulmonary arterial pressure (mPAP) decreasing by 29.5% at 24 weeks. The trial involves 25 patients receiving sotatercept, with a focus on exercise capacity and oxygen uptake. The results position sotatercept as a potential cornerstone therapy for PAH.
Acceleron Pharma (Nasdaq: XLRN) presented new data from the PULSAR Phase 2 trial of sotatercept for pulmonary arterial hypertension (PAH) at the AHA 2020 Scientific Sessions. The trial showed improvements in right ventricular-pulmonary arterial (RV-PA) coupling and right ventricular (RV) function in patients already on PAH therapies. Sotatercept demonstrated potential as a transformative treatment option, with a planned Phase 3 registrational trial, STELLAR, expected to start soon. The drug is currently not approved for use.
Acceleron Pharma (Nasdaq:XLRN) announced updates from its PULSAR and SPECTRA Phase 2 clinical trials of sotatercept for pulmonary arterial hypertension (PAH), to be presented at the AHA Scientific Sessions 2020. The PULSAR trial's echocardiography data, which received the AHA’s “Cardiopulmonary Best Abstract” award, indicates improvements in right ventricular function and pulmonary arterial pressure. The SPECTRA trial results will evaluate peak oxygen uptake in PAH patients. Sotatercept has shown potential as a backbone therapy for PAH.
